6,678 trials
Hepatitis C, Chronic
Primary: The Percentage of Participants Who Achieved a Sustained Virologic Response (SVR) — 56.41; 67.07 Percentage of participants — p=0.1651
Malaria · Falciparum
Primary: Percentage of Participants With Auditory Abnormalities at Day 7 Assessed by Auditory Brainstem Response (ABR) Wave III Latency Changes on Day 7(a Type of Hearing Test)…
Genital Herpes
Primary: Investigator Assessed Time to Healing of All Non-aborted Genital Herpes Lesions — 5.38; 4.79 Days — p=0.4161
Attention-Deficit/Hyperactivity Disorder (ADHD)
Primary: Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Combined Attention and Deportment Scores at 10, 11, and 12 Hour (Averaged) Post-dose…
Parkinson's Disease With End of Dose Wearing Off
Primary: Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to Week 4 — -3.7; -1.8 Units on a scale
Depression
Primary: Remission — 58; 45 Percentage of participants — p=0.14
Parkinson's Disease
Primary: Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living [ADL]) Score From Baseline to Month 3 — -2.5; -0.5 Units on a scale
Postoperative Pain
Primary: Population Pharmacokinetic/Pharmacodynamic (PK/PD) Model for Hydromorphone: Clearance (Cl) — 114 L/hour
Alzheimer's Disease
Primary: Percentage of Participants Treated by Rivastigmine 10 cm^2 Patch for at Least 8 Weeks Who Completed the Study — 74.2 Percentage of participants
Osteoporosis
Primary: Change From Baseline in Urine N-telopeptide of Type 1 Collagen (NTx.) — 49.054; 44.460; 23.676; 34.183 nM BCE/mM Cr
Hypertension · Diastolic Dysfunction
Primary: Change in Lateral Mitral Annular Myocardial Relaxation Velocity — 1.544; 1.476 cm/s
Asthma
Primary: Mean Percent Change in Lumbar Spine Bone Mineral Density (BMD) From the Averaged Baseline Value to the Endpoint of Treatment Time Point — 0.7; 0.9; 1.1; 1.2 percentage…
End Stage Renal Disease
Primary: Number of Participants With Mean PTH ≤ 300 pg/mL — 262; 41 Participants — p=<0.001
Diabetes Mellitus, Type 2
Primary: Adjusted Percent Change From Baseline in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) at Week 52 — -1.24 percent change
Breast Cancer
Primary: Overall Survival — 505 Days